Literature DB >> 2229392

Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.

R T Espejo1, P Uribe.   

Abstract

Analysis by radioimmunoprecipitation of serum samples from 27 different human immunodeficiency virus type 1 (HIV-1)-infected individuals residing in Chile showed that the sera of 26% of these individuals also react with glycoprotein gp125 of HIV type 2 (HIV-2). This cross-reaction seems to reflect a qualitative difference among infected individuals, because the titer of antibodies against gp120 of HIV-1 in the cross-reacting samples did not differ significantly from that in the non-cross-reacting samples. Most of the HIV-1-seropositive sera, including many that did not react with gp125 of HIV-2, reacted with gp140, the precursor of HIV-2 glycoproteins. The observed cross-reactions allowed us to distinguish three groups of HIV-1-infected individuals: (i) those whose sera react with both gp140 and gp125, (ii) those whose sera react with gp140, and (iii) those whose sera react with neither of these glycoproteins. The possible cause and significance of these differences is under study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2229392      PMCID: PMC268113          DOI: 10.1128/jcm.28.9.2107-2110.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  HIV infection in Brazil.

Authors: 
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Simultaneous seropositivity to HIV-1 and HIV-2 in Italian drug abusers.

Authors:  S Buttò; P Verani; F Titti; G Rezza; L Sernicola; G B Rossi
Journal:  AIDS       Date:  1988-04       Impact factor: 4.177

4.  Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing.

Authors:  M A Rey; B Krust; A G Laurent; L Montagnier; A G Hovanessian
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Double HIV-1 and HIV-2 seropositivity among blood donors.

Authors:  C Foucault; O Lopez; G Jourdan; J J Fournel; P Perret; J C Gluckman
Journal:  Lancet       Date:  1987-07-18       Impact factor: 79.321

Review 6.  Practical diagnostic testing for human immunodeficiency virus.

Authors:  J B Jackson; H H Balfour
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Human immunodeficiency virus type 2 infection associated with AIDS in West Africa.

Authors:  F Clavel; K Mansinho; S Chamaret; D Guetard; V Favier; J Nina; M O Santos-Ferreira; J L Champalimaud; L Montagnier
Journal:  N Engl J Med       Date:  1987-05-07       Impact factor: 91.245

8.  HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil.

Authors:  E Cortes; R Detels; D Aboulafia; X L Li; T Moudgil; M Alam; C Bonecker; A Gonzaga; L Oyafuso; M Tondo
Journal:  N Engl J Med       Date:  1989-04-13       Impact factor: 91.245

9.  Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections.

Authors:  T F Schulz; W Oberhuber; J M Hofbauer; P Hengster; C Larcher; L C Gürtler; R Tedder; H Wachter; M P Dierich
Journal:  AIDS       Date:  1989-03       Impact factor: 4.177

10.  Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.

Authors:  F D Veronese; A L DeVico; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

View more
  1 in total

1.  Reactivity patterns and infection status of serum samples with indeterminate Western immunoblot tests for antibody to human immunodeficiency virus type 1.

Authors:  E Ramirez; P Uribe; D Escanilla; G Sanchez; R T Espejo
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.